KineMed, Inc. develops and commercializes proprietary biomarker platform technology. The company focuses on applying its proprietary biomarker platform technology to drug development, prescription, and non-prescription medical diagnostics and the pairing of drugs with diagnostic biomarker tests. It plans to commercialize biomarkers in the areas of muscle biology, fibrotic diseases, neurodegenerative diseases, cardiometabolic diseases, skin care, and cancer. KineMed, Inc. develops and markets assays of molecular kinetics for use in drug development and advanced medical diagnostics. The assays utilize proprietary bio-kinetic assay measurement technologies invented and developed at the University of California, Berkeley, and the University of California, San Francisco.
